Received: 25 March 2022
Accepted: 23 August 2022
First Online: 12 September 2022
: All authors has the following conflict of interest: The authors are the employees and stockholders of Kaken Pharmaceutical Co., Ltd. Kaken Pharmaceutical Co., Ltd. discovered Clenafin/Jublia, a topical onychomycosis treatment product that contains efinaconazole. Clenafin and Jublia is commercialized in Japan by Kaken Pharmaceutical Co., Ltd and the United States/Canada by Bausch Health Companies Inc., respectively.
: The animal experiments were approved by the Animal Experiments Committee of Kaken Pharmaceutical Co., Ltd. and were conducted following the ethical rules for the conduct of animal experiments in Kaken Pharmaceutical, Co., Ltd (Approval No. K16-236 and K17-071).